When including results from five outcome trials with SGLT2 inhibitors across therange of LVEF (DAPA-HF, EMPEROR-Reduced, DELIVER, EMPEROR-Preserved and SOLOIST),the use of SGLT2 inhibitors as compared with placebo showed a reduction in therisk of cardiovascular death or HF hospitalization over an average of 23 monthsof follow-up, independent of LVEF, with a number needed to treat of 25 [41]. This evidence concerns the gene SLC5A2 and hydrops fetalis.